<DOC>
	<DOCNO>NCT00429273</DOCNO>
	<brief_summary>This study evaluate effectiveness single drug versus combination drug treat attention deficit hyperactivity disorder child .</brief_summary>
	<brief_title>Single Versus Combination Medication Treatment Children With Attention Deficit Hyperactivity Disorder</brief_title>
	<detailed_description>Attention deficit hyperactivity disorder ( ADHD ) one common childhood mental disorder . Children ADHD impair function multiple setting , include home school . They also difficulty relate peer . If leave untreated , disorder may cause adverse effect last adolescence adulthood . Stimulant medication , methylphenidate , effective reduce ADHD symptom short-term basis . However , long-term benefit academic general function current ADHD therapy demonstrate . Focalin XR stimulant medication FDA-approved treating ADHD . Guanfacine another medication currently approve treatment hypertension , long use treat ADHD . This study determine effectiveness combination Focalin XR guanfacine enhance cognitive function improve long-term benefit ADHD treatment . Participants study randomly assign one three treatment regimen : Methylphenidate ( Focalin XR ) placebo ; guanfacine placebo ; Focalin XR guanfacine . The study conduct two phase : 8-week double-blind treatment phase 12-month open-label treatment phase . In Phase I , one third participant receive placebo initial 4 week , follow Focalin XR alone remain 4 week . All participant receive assign medication full 8 week . All participant attend two study visit prior begin treatment one study visit per week throughout Phase I . At end Phase I , treatment assignment unblinded . Participants experienced adequate improvement assign treatment continue Phase II medication ( ) additional 12 month . Participants attend study visit per month end study . Study visit include self-report measure , clinical assessment , cognitive testing . Participants also undergo four electroencephalography ( EEG ) test two fMRI scan course study . All Phase II participant receive follow-up telephone call 1 month final study visit .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Guanfacine</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<mesh_term>Dexmethylphenidate Hydrochloride</mesh_term>
	<criteria>Diagnosis DSMIV ADHD KSADSPL confirm clinical interview Clinical Global ImpressionSeverity score least 4 ADHD Resided primary caretaker least 6 month prior study entry History autism , pervasive developmental disorder , chronic tic disorder , psychosis , bipolar disorder Current major depression panic disorder Systolic diastolic blood pressure screen great 95th percentile less 5th percentile age body mass index ( BMI ) Any medical condition might make stimulant alpha agonist therapy medically inadvisable Need chronic use medication central nervous system effect Pregnant , breastfeeding , beyond menarche positive urine pregnancy test History structural heart defect , syncope , faint exercise Clinically significant cardiac abnormality determine echocardiogram ( ECG ) study entry Mental retardation determine clinical functional assessment IQ estimate le 70 base Wechsler Adult Intelligence Scale ( WAIS ) subtests</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>ADHD</keyword>
	<keyword>Guanfacine</keyword>
	<keyword>Methylphenidate</keyword>
	<keyword>Focalin XR</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Cognitive function</keyword>
	<keyword>Combination therapy</keyword>
</DOC>